XTRA:FREHealthcare
Fresenius SE KGaA (XTRA:FRE) Lifts Guidance After Strong Q2, Is The Upside Already Priced In?
Why Fresenius SE KGaA (XTRA:FRE) is back in focus after Q2 earnings
Fresenius SE KGaA (XTRA:FRE) has moved back onto investors’ radar after raising its full year core EPS growth guidance to 10% to 15% alongside Q2 results that outpaced previous performance metrics.
The company reported Q2 2026 sales of €5,945 million compared with €5,650 million a year earlier, while net income was €382 million versus €330 million. Basic earnings per share from continuing operations reached €0.68 compared...